The Latest Breaking News from Catalyst

A niche piece of technology used by scientists and researchers to rapidly work out the dangers and effects of natural hazard events is winning acclaim and international interest

Employability course created by company related to job agency labelled a ‘waste of time, waste of resources’ by one jobseeker

The teams will now go on to Co-Founders+ where they'll be given mentors and specialists to accelerate their ideas

The winner of the influential competition will take home £25,000

Nearly 20 years ago, Aotearoa – and Catalyst – were at the forefront of an e-learning revolution. Now, with the creation of Te Pūkenga, there's a chance to do it again, writes Don Christie

Catalyst Biosciences Inc (NASDAQ:CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue…

Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million.

A scheme spearheaded by Newcastle's National Centre for Ageing and the North of Tyne Combined Authority launches to businesses on May 25

The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a brutal start to 2022, down 12.1% year-to-date. Robinhood Markets Inc (NASDAQ: HOOD) has been one of the worst performers of all so far this year, dropping 43.3%.